Ospina-Serrano A V, Collazo-Lorduy A, Azkona-Uribelarrea E, Guillen-Sentís P, Aparisi F, López R, Cruz P, Valdivia A, Cordeiro P, Olivares-Hernández A, Blanco M, Casas-Cornejo R, Carcereny E, Dómine M, Antoñanzas M, Blasco-Cordellat A, Peralta D, Sereno M, Cardeña-Gutiérrez A, Romão R, Losada B, Avendaño A C, Suay-Montagud G, Moran T, Ortega-Gallastegi B, Calvo V, Arango N, Ramos P, Triana I, Provencio-Pulla M
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
ESMO Open. 2025 Apr;10(4):104539. doi: 10.1016/j.esmoop.2025.104539. Epub 2025 Apr 2.
Patients with lung cancer may suffer from sexual dysfunction (SD) related to oncological treatment. This is an under-recognized condition among clinicians. The aim of this study was to describe the prevalence of SD in a multicenter cohort of patients.
This multicenter, cross-sectional, observational study was conducted between July 2023 and February 2024. Sexual function was assessed by patient-reported outcome (PRO) system using sex-specific questionnaire. Descriptive analysis and evaluation of differences between categorical variables were carried out. Associations between clinical characteristics and SD were assessed by logistic regression.
Four hundred and forty-eight patients from 24 hospitals in Spain, Colombia, Argentina, and Portugal were included. Of these, 277 (61.83%) were male and 365 (81.48%) had metastatic disease. Two hundred and eighty-four patients (63.39%) reported the onset of SD following the initiation of oncological treatment. Males and females reported a high frequency of severe impairment of sexual response phases, which was twice as high in females (P= 0.001). Female sex was a factor for severe impairment of desire, arousal, and orgasm [odds ratio (OR) 3.72, 95% confidence interval (CI) 2.48-5.60, P= 0.001] and decreased sexual activity (OR 1.98, 95% CI:1.17-3.19, P = 0.01), in addition to age over 65 years (OR 3.86, 95% CI 1.01-15.25, P= 0.004) and high educational level (OR 0.29, 95% CI 0.09-0.94, P= 0.0040). Patients from Portugal and Latin America were more likely to report dissatisfaction with sexual activity (OR 3.75, 95% CI 1.06-13.22, P= 0.0039). Female sex (OR 3.53, 95% CI 1.88-6.6, P 0.001), smoking history (OR 1.77, 95% CI 1.01-4.01, P= 0.04), and obesity (OR 1.70 95% CI 1.01-3.16, P= 0.05) were associated with global sexual dissatisfaction.
Our patients with lung cancer had a high prevalence of SD after initiation of oncological treatment. There was remarkable sex disparity in the frequency and severity of this disorder as well as an important influence of sociocultural factors in the clinical presentation.
肺癌患者可能会因肿瘤治疗而出现性功能障碍(SD)。这是临床医生中未得到充分认识的一种情况。本研究的目的是描述多中心队列患者中SD的患病率。
这项多中心、横断面、观察性研究于2023年7月至2024年2月进行。性功能通过患者报告结局(PRO)系统使用针对性别的问卷进行评估。进行了描述性分析以及分类变量之间差异的评估。通过逻辑回归评估临床特征与SD之间的关联。
纳入了来自西班牙、哥伦比亚、阿根廷和葡萄牙24家医院的448名患者。其中,277名(61.83%)为男性,365名(81.48%)患有转移性疾病。284名患者(63.39%)报告在肿瘤治疗开始后出现SD。男性和女性均报告性反应阶段严重受损的频率较高,女性的这一频率是男性的两倍(P = 0.001)。女性是性欲、性唤起和性高潮严重受损的一个因素[比值比(OR)3.72,95%置信区间(CI)2.48 - 5.60,P = 0.001]以及性活动减少的因素(OR 1.98,95% CI:1.17 - 3.19,P = 0.01),此外65岁以上年龄(OR 3.86,95% CI 1.01 - 15.25,P = 0.004)和高教育水平(OR 0.29,95% CI 0.09 - 0.94,P = 0.0040)也是相关因素。来自葡萄牙和拉丁美洲的患者更有可能报告对性活动不满意(OR 3.75,95% CI 1.06 - 13.22,P = 0.0039)。女性性别(OR 3.53,95% CI 1.88 - 6.6,P 0.001)、吸烟史(OR 1.77,95% CI 1.01 - 4.01,P = 0.04)和肥胖(OR 1.70 95% CI 1.01 - 3.16,P = 0.05)与总体性不满意相关。
我们的肺癌患者在肿瘤治疗开始后SD患病率较高。这种疾病在频率和严重程度上存在显著的性别差异,以及社会文化因素在临床表现中具有重要影响。